Clinical Trials Logo

Clinical Trial Summary

This phase II trial is studying the side effects and how well ixabepilone works in treating patients with persistent or recurrent uterine cancer. Drugs used in chemotherapy, such as ixabepilone, work in different ways to stop the growth of tumor cells, either by killing the cells of by stopping them from dividing.


Clinical Trial Description

PRIMARY OBJECTIVES:

I. To determine the response rate of ixabepilone in patients with persistent or recurrent carcinosarcoma of the uterus.

II. To determine the nature and degree of toxicity of ixabepilone in this cohort of patients.

SECONDARY OBJECTIVES:

I. To determine the duration of progression-free survival and overall survival.

TERTIARY OBJECTIVES:

I. To examine the expression of class III beta-tubulin in carcinosarcoma of the uterus.

II. To explore the association between class III beta-tubulin expression in carcinosarcoma of the uterus and response, progression-free and overall survival.

OUTLINE:

Patients receive ixabepilone IV over 3 hours on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.

After completion of study therapy, patients are followed up every 3 months for 2 years and then every 6 months for 3 years. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01168232
Study type Interventional
Source National Cancer Institute (NCI)
Contact
Status Completed
Phase Phase 2
Start date September 7, 2010
Completion date November 26, 2013

See also
  Status Clinical Trial Phase
Completed NCT01010126 - Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Phase 2
Completed NCT00390234 - Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma Phase 2
Completed NCT00245102 - Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma Phase 2
Completed NCT00025506 - Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus Phase 2
Recruiting NCT05902988 - A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer Phase 1/Phase 2
Recruiting NCT05619913 - EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma Phase 2
Completed NCT00687687 - Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma Phase 2
Completed NCT00114218 - Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer Phase 2
Terminated NCT01367301 - Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Uterine Cancer N/A
Withdrawn NCT03902379 - Web-Based Coping and Communication Skills Intervention in Improving Psychological Adaptation in Patients With Gynecological Cancer N/A
Completed NCT03694262 - The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib) Phase 2
Completed NCT01247571 - Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer Phase 2
Terminated NCT01061606 - Temsirolimus in Treating Patients With Recurrent or Persistent Cancer of the Uterus Phase 2
Completed NCT00075400 - Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer Phase 2
Completed NCT00659360 - AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma Phase 2
Completed NCT00238121 - Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer Phase 2
Recruiting NCT05147558 - A Study of Pembrolizumab With Lenvatinib in Women With Advanced Uterine Carcinosarcoma Phase 2
Active, not recruiting NCT00954174 - Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer Phase 3
Completed NCT00478426 - Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer Phase 2
Recruiting NCT05229601 - A Study of HFB301001 in Adult Patients With Advanced Solid Tumors Phase 1